We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
Read MoreHide Full Article
Key Takeaways
MyoSure and Fluent have powered HOLX's Surgical growth at a 7.6% CAGR over the last decade.
HOLX sees solid uptake for Fluent Pro and growing demand abroad, boosting Surgical momentum.
Acquisitions like Acessa and Gynesonics enhance HOLX's fibroid treatment and global market reach.
The growing prevalence of gynecological diseases and increasing government investments to improve women’s health are fueling the demand for gynecology surgical instruments. According to Zion Market Research, the market is projected to expand at a compound annual growth rate (CAGR) of 8.26% through 2024-2032. Hologic’s (HOLX - Free Report) GYN Surgical business is well-positioned to benefit, having delivered a 7.6% CAGR over the past decade, driven by the MyoSure suite of devices and the related Fluent fluid management system.
In late 2024, the company launched the Fluent Pro system — the next generation of fluid management designed to enhance MyoSure’s performance and user experience. The product is seeing robust uptake and is expected to contribute meaningfully to Surgical’s performance this year. Meanwhile, International Surgical remains Hologic’s leading revenue driver, backed by ongoing investments in market development and awareness for Hologic’s minimally invasive GYN products. These efforts are laying a strong foundation for sustained Surgical growth globally.
Legacy NovaSure devices are gaining solid momentum overseas, particularly in Europe, despite facing declining U.S. volumes. The company sees tremendous runway for expansion as it continues to introduce the platform to new geographies. Myosure’s international growth is outpacing domestic gains, highlighting the significant untapped opportunity in these markets.
Additionally, inorganic investment has played a crucial role in the Surgical growth strategy. The acquisition of Acessa Health in 2020 added a highly complementary fibroid treatment product, while the 2021 buyout of Bolder Surgical enhanced the laparoscopic portfolio with advanced vessel sealing and dissection tools. In January 2025, Hologic purchased Gynesonics, a developer of minimally invasive solutions for women’s health. The addition further expands the company’s fibroid treatment lineup with the market-leading Sonata System and also supports the company’s international expansion efforts.
Hologic’s GYN Surgical Rivals
In the GYN Surgical space, Hologic mainly faces competition from large, full-suite surgical solution companies such as Johnson & Johnson (JNJ - Free Report) and Medtronic (MDT - Free Report) .
J&J’s MedTech business segment posted worldwide sales of $8 billion in the first quarter of 2025, 4.1% year-over-year growth, including 5.1% in the United States and 3% internationally. The unit recently announced the U.S. launch of the ETHICON 4000 Stapler, designed to manage tissue complexities and enhance staple line integrity to reduce risk factors for surgical leaks and bleeding complications across specialties. Meanwhile, Medtronic’s Medical Surgical Portfolio increased 2% in the fourth quarter of fiscal 2025, with strong growth in emerging markets and advanced energy. Growth is expected to improve as MDT expands and launches its Hugo soft tissue robotic platform.
HOLX Stock Performance, Valuation and Estimates
Year to date, Hologic shares have declined 8.7% compared with the industry’s 9.1% fall.
Image Source: Zacks Investment Research
Hologic is trading at a forward 12-month earnings multiple of 14.85, discounted than the industry average of 28.39. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
Consensus estimates for the company’s fiscal 2025 and 2026 earnings are showing a bearish trend.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
Image: Bigstock
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
Key Takeaways
The growing prevalence of gynecological diseases and increasing government investments to improve women’s health are fueling the demand for gynecology surgical instruments. According to Zion Market Research, the market is projected to expand at a compound annual growth rate (CAGR) of 8.26% through 2024-2032. Hologic’s (HOLX - Free Report) GYN Surgical business is well-positioned to benefit, having delivered a 7.6% CAGR over the past decade, driven by the MyoSure suite of devices and the related Fluent fluid management system.
In late 2024, the company launched the Fluent Pro system — the next generation of fluid management designed to enhance MyoSure’s performance and user experience. The product is seeing robust uptake and is expected to contribute meaningfully to Surgical’s performance this year. Meanwhile, International Surgical remains Hologic’s leading revenue driver, backed by ongoing investments in market development and awareness for Hologic’s minimally invasive GYN products. These efforts are laying a strong foundation for sustained Surgical growth globally.
Legacy NovaSure devices are gaining solid momentum overseas, particularly in Europe, despite facing declining U.S. volumes. The company sees tremendous runway for expansion as it continues to introduce the platform to new geographies. Myosure’s international growth is outpacing domestic gains, highlighting the significant untapped opportunity in these markets.
Additionally, inorganic investment has played a crucial role in the Surgical growth strategy. The acquisition of Acessa Health in 2020 added a highly complementary fibroid treatment product, while the 2021 buyout of Bolder Surgical enhanced the laparoscopic portfolio with advanced vessel sealing and dissection tools. In January 2025, Hologic purchased Gynesonics, a developer of minimally invasive solutions for women’s health. The addition further expands the company’s fibroid treatment lineup with the market-leading Sonata System and also supports the company’s international expansion efforts.
Hologic’s GYN Surgical Rivals
In the GYN Surgical space, Hologic mainly faces competition from large, full-suite surgical solution companies such as Johnson & Johnson (JNJ - Free Report) and Medtronic (MDT - Free Report) .
J&J’s MedTech business segment posted worldwide sales of $8 billion in the first quarter of 2025, 4.1% year-over-year growth, including 5.1% in the United States and 3% internationally. The unit recently announced the U.S. launch of the ETHICON 4000 Stapler, designed to manage tissue complexities and enhance staple line integrity to reduce risk factors for surgical leaks and bleeding complications across specialties. Meanwhile, Medtronic’s Medical Surgical Portfolio increased 2% in the fourth quarter of fiscal 2025, with strong growth in emerging markets and advanced energy. Growth is expected to improve as MDT expands and launches its Hugo soft tissue robotic platform.
HOLX Stock Performance, Valuation and Estimates
Year to date, Hologic shares have declined 8.7% compared with the industry’s 9.1% fall.
Image Source: Zacks Investment Research
Hologic is trading at a forward 12-month earnings multiple of 14.85, discounted than the industry average of 28.39. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
Consensus estimates for the company’s fiscal 2025 and 2026 earnings are showing a bearish trend.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.